NCT03382574 2022-06-14Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-OophorectomyNational Cancer Institute (NCI)Phase EARLY_PHASE1 Terminated2 enrolled